Blog
RSS FeedPosted by Michael Wonder on 16 Sep 2021
Nivolumab in skin cancer: additional benefit upgraded on the basis of an indirect comparison
16 September 2021 - For nivolumab (Opdivo), the pharmaceutical company was able to achieve a significantly better result in a second ...
Posted by Michael Wonder on 15 Sep 2021
Venetoclax in acute myeloid leukaemia: indication of a considerable added benefit
15 September 2021 - Third new area of application/those affected still live a good year on average - and thus ...
Posted by Michael Wonder on 16 Aug 2021
Spinal muscular atrophy: second and third active ingredients undergo benefit assessment
16 August 2021 - With risdiplam there is a hint of an added benefit for spinal muscular atrophy type 1, ...
Posted by Michael Wonder on 16 Aug 2021
Lanadelumab in hereditary angioedema: added benefit not proven
16 August 2021 - The active ingredient has exceeded the sales limit for the simplified orphan drug assessment. There are no ...
Posted by Michael Wonder on 09 Aug 2021
Quality assurance requirements of the G-BA also apply to new CAR-T cell therapy
5 August 2021 - The Federal Joint Committee (G-BA) today evaluated the new cancer drug with the trade name Tecartus and ...
Posted by Michael Wonder on 05 Jul 2021
Remdesivir in COVID-19: indication of considerable added benefit for a part of the patients
1 July 2021 - COVID-19 patients with pneumonia who do not yet require high-flow oxygen therapy benefit from remdesivir: they recover ...
Posted by Michael Wonder on 01 Mar 2021
Nusinersen in spinal muscular atrophy: indication of considerable added benefit in children with an early onset of the disease
1 March 2021 - The treatment delays permanent ventilation of the children and extends life. In addition, the children develop more ...
Posted by Michael Wonder on 01 Mar 2021
Dapagliflozin in chronic heart failure: hint of added benefit
1 March 2021 - Diabetes drug is also effective in symptomatic chronic heart failure with reduced pump function. However, the additional ...
Posted by Michael Wonder on 04 Jan 2021
Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR
4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are ...
Posted by Michael Wonder on 03 Dec 2020
Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment
3 December 2020 - Inappropriate treatment in the control arm makes fair comparison impossible. ...
Posted by Michael Wonder on 19 Nov 2020
Trifarotene in moderate acne: no study data for the assessment of the added benefit
16 November 2020 - Only studies with placebo comparisons despite many affected people and existing treatment alternatives. ...
Posted by Michael Wonder on 17 Aug 2020
Castration-resistant prostate cancer with a high risk of metastasis: enzalutamide has an additional benefit
17 August 2020 - New data from the PROSPER study shows benefit in overall survival. ...
Posted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...
Posted by Michael Wonder on 05 Jul 2020
Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority
1 July 2020 - Informative comparative data are missing / resistance situation not sufficiently considered in approval studies. ...
Posted by Michael Wonder on 15 Jun 2020
Romosozumab in osteoporosis: considerable added benefit for women after menopause
15 June 2020 - Fewer vertebral fractures and fewer other typical fractures in post-menopausal women with severe osteoporosis at high ...